Please login to the form below

Not currently logged in
Email:
Password:

VC firm expands team, appoints Genzyme and Lilly veterans

New roles for James Geraghty, Steven Paul, Daniel Lynch and John Maraganore

Third Rock Steven PaulUS venture capital company Third Rock Ventures has expanded its team by appointing a number of industry heavyweights.

The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies.

James Geraghty, who has spent 20-years at Genzyme, becomes entrepreneur-in-residence, while the former president of Lilly Research Laboratories, Steven Paul (pictured right), takes on an increased role at Third Rock with a position as a venture partner.

Third Rock Daniel LynchAlso joining Third Rock as venture partners are Daniel Lynch (pictured right), a former CEO of ImClone Systems, and Alnylam's CEO John Maraganore. 

Robert Tepper, partner at Third Rock Ventures, said: “These leaders have demonstrated - through decades of experience - their ability to integrate science and business.

“The depth of their expertise across commercial, business development, R&D, drug discovery and product development will be invaluable to Third Rock as we focus on translating scientific innovation into exceptional companies that make a difference for patients.”

15th May 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics